IOM suggests FDA monitor drugs' safety regularly

The Institute of Medicine recommended the FDA oversee drug safety regularly to address additional risks. The FDA indicated reservation about the cost of "life cycle" drug monitoring because this could compromise other regulatory tasks.

View Full Article in:

U.S. needs better way to track drug safety - study - Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA